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Background: Data on the prevalence and complications of gestational diabetes are very scarce in Cameroon.
The aim of this study was to evaluate the uptake of screening for gestational diabetes and assess the immediate
post-partum outcome of hyperglycemic parturient mothers and perinatal outcome of their babies.
Methods: A prospective cohort study was held at the Maternity of the Yaoundé Central Hospital from March to
June 2013. One hundred volunteer women in labor without overt diabetes mellitus and having fasted for 8 to 12 h
were recruited. No intervention was given. A clinical examination was done and capillary glucose recorded. Parturient
women were categorized into two groups (hyperglycemic and non-hyperglycemic subjects) based on glycemia results
interpreted according to the International Association of Diabetes and Pregnancy Study Groups. Mothers’ clinical
examination was repeated and neonates examined immediately after delivery. Perinatal outcomes associated with
maternal hyperglycemia during labor were assessed using relative risks. A p value <0.05 was considered statistically
significant.
Results: One hundred women with a mean age of 27 (SD 6) years were recruited. Of them, 22 (22 %) had already
been screened for gestational diabetes at baseline. Thirty-one (31 %) were diagnosed with hyperglycemia during labor,
and this condition was highly associated with macrosomia in neonates (RR = 8.9, 95 % CI 2.70–29.32; p < 0.001). Other
complications associated with maternal hyperglycemia during labor were perineal tears, cesarean section, and
intrauterine fetal death, though the association was not statistically significant.
Conclusions: The main finding of this study is that maternal hyperglycemia during labor is highly associated with
macrosomia in neonates. About a third of mothers were concerned with hyperglycemia during labor, and gestational
diabetes was insufficiently screened in this series.
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According to the World Health Organization (WHO),
gestational diabetes mellitus (GDM) stands for any
degree of glucose intolerance, with onset or first recog-
nition during pregnancy, no matter the necessary treat-
ment and post-partum evolution [1, 2]. It makes up to
90–95 % of cases of diabetes mellitus seen in pregnant
women [3]. There are conflicting reports about its
screening, adequate diagnostic tools, and adapted fasting
glucose thresholds [4]. However, the most convincing
study on adverse outcome associated with maternal glu-
cose intolerance to date is the HAPO (Hyperglycemia
and Adverse Pregnancy Outcomes) study [5, 6], from
which most of internationally acceptable criteria for
diagnosis and classification of GDM are derived. GDM
prevalence ranges from 2 to 22 % of all pregnancies. Eth-
nicity, the screening method, and the glucose threshold
used can explain this wide gap. Of note, prevalence
increases with decreasing glucose thresholds. In the
United States of America (USA), the prevalence of GDM
was 2.8 % in 2007; it was 3.8 and 4.5 % in France in
2004 and 2005, respectively [7]. In sub-Saharan Africa,
the prevalence of GDM varies from 3.7 % in Ethiopia
(1999) to 3.8 % in South Africa (2007) and 6.3 % in
Cameroon (2013) [8–10].
Previous studies report a number of maternal and fetal
complications of GDM. However, their proof is limited by
the lack of a consensus definition which makes their re-
sults difficult to compare. Furthermore, poor outcomes
associated with different degrees of impaired glucose tol-
erance can be explained by a number of confounding
characteristics such as obesity, an older maternal age, and
maternal comorbid conditions which are not usually ad-
justed in those studies [6]. With respect to conflicting re-
ports on screening and diagnosis of GDM, questions can
be raised about cost-effectiveness and benefit of screening
and treating GDM [6], especially in resource-limited
countries such as Cameroon. So, it is not yet systematic-
ally screened, and a number of cases can therefore be
missed, leading to a high risk of maternal and fetal adverse
outcome. In order to assess the impact of missed oppor-
tunities of diagnosis, we carried out this study with an aim
to evaluate the uptake of screening for GDM and assess
the immediate post-partum outcome of hyperglycemic
parturient mothers and perinatal outcome of their babies.
Methods
Setting, participants, and procedure
We conducted a prospective cohort study between
March and June 2013 at the Maternity of the Yaoundé
Central Hospital. At baseline, we included all pregnant
women who came to deliver at the study site during the
study period, who had fasted for 8 to 12 h, and who con-
sented to participate in the study. We excluded womenwith overt diabetes mellitus. No intervention was given.
Each participant underwent a thorough clinical evalu-
ation, with focus on demographic parameters, pregnancy
follow-up and evolution details, past medical comorbid
conditions, and present physical examination’s findings.
A capillary glycemia was performed, and women were
divided into two groups (non-hyperglycemic and hyper-
glycemic individuals), based on glycemia results inter-
preted as recommended by the International Association
of Diabetes and Pregnancy Study Groups (IADPSG) cri-
teria. The HAPO study was used as the basis of these
criteria [6]. Women were then followed up during the
labor in delivery rooms until delivery. Immediately after
delivery, they were re-examined. Newborns were also ex-
amined and followed up. All women and newborns were
followed up for at least 48 h. In case a perinatal compli-
cation occurred, the follow-up period was prolonged
until the health status of the woman or the newborn was
stabilized or death occurred.
Statistical analyses
This was a pilot study based on a convenient sample
and, accordingly, no formal power estimation. Data were
entered, coded, and analyzed using Epi-info 3.5.3 soft-
ware. Variables are expressed as mean with standard de-
viation (SD) or count with percentage. The chi-square
test or the Fischer exact test where appropriate were
used to compare proportions. Relative risk was used to
assess the perinatal outcomes associated with maternal
hyperglycemia during labor. A p value <0.05 was consid-
ered statistically significant.
Results
A total of 100 women were recruited. Their mean age
was 27 (SD 6) years, with 60 % of them aged between 20
and 30 years. All the participants were educated. The
high school level of education was the most represented
(56 %, n = 56), followed by the university level (32 %, n =
32), and then the primary level (29 %, n = 29). Only 22
(22 %) of them had had an antenatal screening or diag-
nosis of gestational diabetes at baseline. And of these,
only one (5 %) had been screened between the 24th and
the 28th week (Table 1). Thirty-one parturient women
(31 %) had hyperglycemia (Table 2).
As shown in Table 3, perineal tears, cesarean section
delivery, intrauterine fetal death, and neonatal macroso-
mia were all related to maternal hyperglycemia. But the
relation was significant only for neonatal macrosomia
(RR = 8.9, 95 % CI 2.70–29.32; p < 0.001).
Discussion
This study confirms the hypothesis of a very low rate of
detection of GDM in our clinical settings, with only ap-
proximately a quarter of parturient women who were
Table 1 Antenatal screening/diagnosis of gestational diabetes
in parturient women
Variables Number Percentage
Antenatal screening of gestational diabetes (N = 100)
Yes 22 22
No 78 78
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about a third of delivering women were diagnosed with
hyperglycemia in the labor room, and this condition was
highly associated with neonatal macrosomia.
Most of the delivering women missed the opportunity
of GDM detection early in the pregnancy. This reflects
the non-application of available guidelines regarding de-
tection and management of GDM in our clinical set-
tings. In fact, it is recommended to realize GDM
detection as from the first antenatal visit by a fasting gly-
cemia and an oral tolerance glucose test at 24–28 weeks’
gestation, to prevent an adverse pregnancy outcome [6,
11]. A low rate of antenatal screening of this condition is
a well-known problem. Notably, adequate policies of
GDM screening were only recently drawn [11]. Also,
many of the patients in this series had been followed up
elsewhere for their pregnancy and were referred to the
Yaoundé Central Hospital for complicated pregnancy
termination. Even though most women had at least a
high school level, they were not screened for GDM.
Thus, the pregnant woman’s level of education might
not influence the clinician’s practice concerning the de-
tection and management of GDM.
However, the rate of maternal hyperglycemia was
31 %. This is much higher than the rate of GDM (5.2 %)
found in Kinshasa in 2010 [12]. It is still much higher
than the 5–17 % rate of GDM found in Cameroon of
the same year (unpublished data). Those studies were
carried out before the IADPSG criteria were published.
They used different diagnostic criteria. It is therefore dif-
ficult to compare their results to those of this study. Fur-
thermore, it is well known that using the HAPO
thresholds increases the proportion of women diagnosed
with GDM, since it proved that even at lesser maternalTable 2 Maternal glycemia during labor
Glycemia (g/l) Number Percentage
<0.80 40 40
0.80–0.91 29 29
≥0.92 31 31glucose thresholds than those diagnosed with diabetes,
there is an increased risk of adverse maternal and peri-
natal outcome [6]. This proportion could have been
more elevated if we had added an intervention such as
the 1-h glucose test [6]. Maternal hyperglycemia and
GDM have been associated with an adverse maternal
and perinatal outcome, as we found in this study. We
observed a non-significant association between perineal
tears, cesarean section delivery, intrauterine fetal death,
and maternal hyperglycemia. These are well-known
complications found in pregnant women presenting with
impaired glucose tolerance. But the effect of hypergly-
cemia in generating these troubles seems minor, and
they are usually attributed to cofounders such as obesity,
an older maternal age, and medical comorbid conditions
co-occurring in GDM patients, rather than to hypergly-
cemia per se [6, 11]. Maternal impaired glucose toler-
ance also prompted a high risk of birth weight large for
gestational age (LGA) in this study, same as Odar et al.
in Uganda in 2004 [13]. The risk of LGA found in this
study was even approximately double of that found in
their study. The HAPO as well as most of all interven-
tional and cohort studies evaluating the perinatal out-
come of maternal hyperglycemia report an increased risk
of LGA. The risk of LGA has a continuous graded rela-
tionship with higher maternal glucose levels [6]. This
can be detected even at lesser glucose levels such as
0.92 g/l used in this study [6, 11]. A higher glucose
threshold in the study of Odar et al. could thus have de-
creased the risk they observed. LGA usually occurs with
excess neonate’s adiposity, neonatal hypoglycemia, and
excess neonate’s cord C-peptide [6]. In fact, excess ma-
ternal blood glucose is transported to the fetal circula-
tion through the placenta. This is firstly responsible for
increase of blood glucose which excessively stimulates
insulin production. Fetal hyperinsulinemia then induces
hypoglycemia observed in the neonate through its ana-
bolic and glycogenolytic pathways. Anabolic reactions
are also responsible for excess adiposity and macroso-
mia [6]. And LGA can lead to overweight/obesity and
even diabetes mellitus in the mother as well as in the
infant [6, 11].
This study has some limitations. The follow-up of par-
turient women makes it possible to draw causal relation-
ships between maternal hyperglycemia and immediate
maternal and perinatal complications in our setting. But
the short duration of follow-up and the lack of some
neonatal biological analyses such as calcemia, bilirubine-
mia, and full blood count have limited the information
that could have been brought by this study. Also, we did
not adjust for confounders. However, the susceptibility
to LGA in case of maternal glucose intolerance that we
observed is said to be independent of confounders. This
might therefore not have affected our finding. Lastly,
Table 3 Maternal and perinatal complications related to maternal hyperglycemia
Complications Hyperglycemia (N = 31) Non-hyperglycemia (N = 69) Relative risk 95 % CI p value
Maternal complications
Perineal tears 4 6 1.48 0.45–4.89 0.52
Caesarian section 6 8 1.67 0.63–4.40 0.30
Instrumental delivery 2 0 10.93 0.54–221.33 0.11
Post-partum hemorrhage 1 0 6.56 0.27–156.74 0.24
Perinatal complications
Macrosomia 12 3 8.90 2.70–29.32 <0.001
Intrauterine death 3 0 15.31 0.81–287.79 0.06
Premature delivery 4 8 1.11 0.36–3.42 0.85
Respiratory distress 2 0 10.93 0.54–221.33 0.11
Rapid neonatal death 0 1 0.72 0.03–17.41 0.84
Intrapartum death 0 1 0.72 0.03–17.41 0.84
95 % CI 95 % confidence interval
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ternal hyperglycemia during labor and neonatal macro-
somia, as maternal hyperglycemia during labor is only
an indicator of probable maternal hyperglycemia during
the third trimester of pregnancy which is the actual cor-
relate of neonatal macrosomia.
Conclusions
Maternal hyperglycemia during labor was highly associ-
ated with neonatal macrosomia. Maternal hyperglycemia
was present in about a third of mothers, and antenatal
screening of gestational diabetes was poor in this setting.
Future large longitudinal prospective and interventional
studies are warranted to confirm these findings.
Acknowledgements
We are grateful to all the parturient women who participated in the study.
Funding
This research did not receive any funding.
Availability of data and materials
Data will be available from the corresponding author upon request.
Authors’ contributions
MD, ES, PN, and NJF were responsible for the study conception and design.
MD, ES, and PN were responsible for the data collection. MD, JJNN, and ME
were responsible for the statistical analysis and interpretation. MD, JJNN, and
ME were responsible for the drafting. MD, ES, JJNN, ME, PH, and NJF were
responsible for the critical discussion and manuscript revision. All authors
were responsible for the decision to submit the final draft. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable
Ethics approval and consent to participate
The study was granted approval by the National Ethical Review Board of the
Cameroon Ministry of Public Health. Written informed consent was obtainedfrom all the participants. The study was conducted in accordance with the
Helsinki Declaration.
Author details
1Department of Internal Medicine and Specialties, Faculty of Medicine and
Biomedical Science, University of Yaoundé I, Yaoundé, Cameroon.
2Laboratory for Molecular Medicine and Metabolism, Biotechnology Center,
University of Yaoundé I, Yaoundé, Cameroon. 3National Obesity Center,
Yaoundé Central Hospital and Faculty of Medicine and Biomedical Sciences,
University of Yaoundé 1, Yaoundé, Cameroon. 4Department of Medicine,
University of Cape Town and Groote Schuur Hospital, Cape Town, South
Africa. 5Medical Diagnostic Center, Yaoundé, Cameroon. 6Department of
Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science,
University of Yaoundé I, Yaoundé, Cameroon.
Received: 23 March 2016 Accepted: 16 August 2016References
1. World Health Organization. The global burden of disease 2000. Geneva:
WHO; 2006.
2. IDF-Africa, WHO-AFRO. The diabetes strategy for Africa. An integrated
strategic plan for diabetes and related health risk. Cape Town: IDF-Africa
and WHO-AFRO; 2006.
3. Petitti DB, DeWitt TG, Gordis L, Gregory KD, Harris R, Isham G, et al.
Screening for gestational diabetes mellitus: U.S. Preventive Services Task
Force recommendation statement. U.S. Preventive Task Force. Ann Intern
Med. 2008;148:759–65.
4. Haute Autorité de Santé. Rapport de synthèse sur le dépistage et le
diagnostic du diabète gestationnel. Paris: HAS; 2005.
5. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR,
Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy
outcomes. N Engl J Med. 2008;358(19):1991–2002.
6. International Association of Diabetes and Pregnancy Study Groups
Consensus panel. International Association of Diabetes and Pregnancy
Study Groups recommendation on the diagnosis and classification of
hyperglycaemia in pregnancy. Diabetes Care. 2010;33(3):676–82.
7. Venditteli F, Rivière O, Crenn-Hébert C, Claris O, Tessier V, Pinquier D, et al.
Audipog perinatal network. Part 1: principal perinatal health indicators,
2004–2005. Gynecol Obstet Fertil. 2008;36(11):1091–100.
8. Mamabolo RL, Alberts M, Steyn NP, Delemarre-van dewaal HA, Levitt NS.
Prevalence of gestational diabetes mellitus and the effect of weight on
measures of insulin secretion and insulin resistance in third-trimester
pregnant rural women residing in the central region of Limpopo province,
South Africa. Diabet Med. 2007;24(3):233–9.
Djomhou et al. Journal of Health, Population and Nutrition  (2016) 35:28 Page 5 of 59. Seyoum B, Kiros K, Haileselase T, Leole A. Prevalence of gestational diabetes
mellitus in rural pregnant mothers in northern Ethiopia. Diabetes Res Clin
Pract. 1999;46(3):247–51.
10. Jao J, Wong M, Van Dyke RB, et al. Gestational diabetes mellitus in HIV-
infected and -uninfected pregnant women in Cameroon. Diabetes Care.
2013;36:e141–2.
11. World Health Organization. Diagnostic criteria and classification of
hyperglycemia first detected in pregnancy. Geneva: WHO; 2013.
12. Tandu-Umba NFB, Paka MA, Mbungu MR, Muls E. Détermination de la
prévalence du diabète gestationnel et des facteurs associés à Kinshasa. Ann
Afr Med. 2010;3(1):321–25.
13. Odar E, Wandabwa J, Kiondo P. Maternal and fetal outcome of gestational
diabetes mellitus in Mulago Hospital, Uganda. Afr Health Sci. 2004;4(1):9–14.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
